Trial Profile
A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Febrile neutropenia
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER
- Sponsors Sandoz
- 05 Jun 2018 Results assessing the safety and efficacy of biosimilar filgrastim in Breast Cancer patients from PIONEER (n=217) and MONITOR-GCSF (n=466) studies, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 28 Oct 2017 Results assessing the efficacy for pooled switched groups to the unswitched reference group (excluding patients who received biosimilar filgrastim alone continuously) during cycles 2-6, published in the Annals of Oncology Journal.
- 06 Jun 2017 Results assessing safety profile of EP2006 from this and other EU registration trial (n=277) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology